These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 495247)

  • 21. [Clinical evaluation of Teronac (mazindol) in the treatment of obesity in children. Part II. Anorectic properties and side effects (author's transl)].
    Gołebiowska M; Chlebna-Sokół D; Kobierska I; Konopińska A; Małek M; Mastalska A; Zwaigzne-Raczyńska J
    Przegl Lek; 1981; 38(3):355-8. PubMed ID: 7017827
    [No Abstract]   [Full Text] [Related]  

  • 22. Double blind cross-over study of a new appetite suppressant AN 448.
    Haugen HN
    Eur J Clin Pharmacol; 1975; 8(1):71-4. PubMed ID: 786676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Drug therapy in obesity].
    Ishii J
    Nihon Rinsho; 1988 Nov; 46(11):2491-6. PubMed ID: 3241376
    [No Abstract]   [Full Text] [Related]  

  • 24. [Results in the treatment of obesity by Mazindol (AN 448 Sandoz) in hospitalized subjects using the method of double-blind trial (author's transl)].
    Kreze A; Velemínsky J; Toman A
    Bratisl Lek Listy; 1976 May; 65(5):537-43. PubMed ID: 788862
    [No Abstract]   [Full Text] [Related]  

  • 25. A double-blind trial of mazindol using a very low calorie formula diet.
    Baird IM; Howard AN
    Int J Obes; 1977; 1(3):271-8. PubMed ID: 363631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Comparative trial on the effects of diet, mazindol, and placebo in the treatment of exogenous obesity (author's transl)].
    Mies R
    Med Klin; 1976 Nov; 71(46):2013-6. PubMed ID: 995040
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical trial with a nonamphetaminic anoretic].
    Campagnoli M
    Rev Iber Endocrinol; 1976; 23(137):463-83. PubMed ID: 794978
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multicentre study comparing mazindol and placebo in obese patients.
    Walker BR; Ballard IM; Gold JA
    J Int Med Res; 1977; 5(2):85-90. PubMed ID: 326596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A double blind controlled trial of a new anorectic agent AN448.
    Woodhouse SP; Nye ER; Anderson K; Rawlings J
    N Z Med J; 1975 Jun; 81(542):546-9. PubMed ID: 1099491
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The clinical evaluation of teronac (Mazindol) in the treatment of children with obesity. Part I. Effect of the drug on somatic patterns and exercise capacity (author's transl)].
    Gołebiowska M; Chlebna-Sokoł D; Mastalska A; Zwaigzne-Raczyńska J
    Przegl Lek; 1981; 38(2):311-4. PubMed ID: 7017826
    [No Abstract]   [Full Text] [Related]  

  • 31. [Effect of mazindol on obesity induced by administration of gold thioglucose].
    Ohminami K; Matsuoka E; Takahashi Y; Shimizu D; Okuda H
    Nihon Yakurigaku Zasshi; 1984 Feb; 83(2):123-32. PubMed ID: 6430760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short-term and long-term clinical evaluation of a non-amphetaminic anorexiant (mazindol) in the treatment of obesity.
    Enzi G; Baritussio A; Marchiori E; Crepaldi G
    J Int Med Res; 1976; 4(5):305-18. PubMed ID: 1028632
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Slowed gastric evacuation accounts for the reduction of food intake by anorectic drugs.
    Jonderko K; Kucio C; Skrzypek D
    Eur J Clin Nutr; 1988 Jul; 42(7):627-31. PubMed ID: 3066620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Activity-mobilizing lipids and blood lipids in patients treated with Mazindol].
    Hasik J; Gryczka AZ; Paluszak J; Tycowa M
    Pol Arch Med Wewn; 1978 Nov; 60(5):401-4. PubMed ID: 724542
    [No Abstract]   [Full Text] [Related]  

  • 35. [Long-term treatment of patients with obesity using mazindol and a reducing diet].
    van Seters AP; Bouwhuis-Hoogerwerf ML; Goslings BM; van Nieuwkoop L; van Slooten H; Struijk-Wielinga T
    Ned Tijdschr Geneeskd; 1982 May; 126(22):990-4. PubMed ID: 7110390
    [No Abstract]   [Full Text] [Related]  

  • 36. [Mazindol in the treatment of obesity in diabetics (author's transl)].
    Felt V; Nedvídková J
    Cas Lek Cesk; 1977 Sep; 116(39):1214-7. PubMed ID: 922789
    [No Abstract]   [Full Text] [Related]  

  • 37. The effect of an anorectic agent (Mazindol) on control of obese diabetics.
    Sanders M; Breidahl H
    Med J Aust; 1976 Oct; 2(15):576-7. PubMed ID: 994969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Mazindol (AN 448 Sandoz) in ambulatory treatment of obesity; its effect on body composition and adipose tissue].
    Rath R; Vondra K; Wenkeová J
    Cesk Gastroenterol Vyz; 1977 Sep; 31(6):389-94. PubMed ID: 589677
    [No Abstract]   [Full Text] [Related]  

  • 39. [Treatment of obesity with mazindol (author's transl)].
    Escher M
    Schweiz Rundsch Med Prax; 1976 Jun; 65(24):751-4. PubMed ID: 981189
    [No Abstract]   [Full Text] [Related]  

  • 40. [Use of mazindol in the dietetic treatment of obesity in patients with essential hypertension].
    Kocemba J; Kawecka-Jaszcz K
    Pol Arch Med Wewn; 1978 Dec; 60(6):517-23. PubMed ID: 366579
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.